BioNexus Gene Lab (BGLC) Common Equity (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Common Equity data on file, last reported at $8.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 4.14% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.1 million (up 4.14% YoY), and the FY2025 full-year result was $8.6 million, up 3.51% from the prior year.
• Common Equity retreated to $8.1 million in Q1 2026, from $8.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $9.7 million in Q4 2023 to a low of $5.6 million in Q2 2023.
• A 5-year average of $7.8 million and a median of $7.8 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 70.7% in 2024 and slipped 27.4% in 2025, its largest moves.
• Tracing BGLC's Common Equity over 5 years: stood at $6.7 million in 2022, then surged by 44.9% to $9.7 million in 2023, then retreated by 13.82% to $8.3 million in 2024, then gained by 3.51% to $8.6 million in 2025, then declined by 6.06% to $8.1 million in 2026.
• Business Quant data shows BGLC's Common Equity at $8.1 million in Q1 2026, $8.6 million in Q4 2025, and $6.8 million in Q3 2025.